Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
Joshua Veatch(University of Washington), Stanley R. Riddell(Fred Hutch Cancer Center), Kelly G. Paulson(Swedish Medical Center), Brenda L. Jesernig(Fred Hutch Cancer Center), Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ernesto Iacucci(Nektar Therapeutics (United States)), Naina Singhi(Fred Hutch Cancer Center), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 9
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654